Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clinical Trial Certification: Companies Say IND Submissions Should Be Exempt

Executive Summary

Several companies say FDA is requiring clinical trial sponsors to submit too much trial information to a new public database, and they particularly oppose certification of investigational new drug submissions

You may also be interested in...



ClinicalTrials.gov Requirements Continue To Baffle Firms And Feds Alike

FDA is continuing to solicit questions about the submissions requirements for ClinicalTrials.gov, even though the formal comments deadline on its initial draft guidance has passed

ClinicalTrials.gov Requirements Continue To Baffle Firms And Feds Alike

FDA is continuing to solicit questions about the submissions requirements for ClinicalTrials.gov, even though the formal comments deadline on its initial draft guidance has passed

Clinical Trial Certification Requirements Under FDAAA May Be “Time Bomb”

The section of the FDA Amendments Act that requires companies to post information about their clinical trials contains a "hidden time bomb," according to I. Scott Bass, a partner at the law firm Sidley Austin

Related Content

UsernamePublicRestriction

Register

PS049806

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel